Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens. The Food and Drug Administration (FDA) has granted accelerated approval to Bizengri ...
Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the US Food and Drug Administration (FDA), marking “an important milestone” in the treatment of cancers with a ...
Dutch biopharma Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer. Bizengri (zenocutuzumab) targets the ...
Bizengri received accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, showing ORRs of 33% and 40%, respectively, with varying DORs. Imfinzi significantly improved ...
The therapy, branded as Bizengri, targets the NRG1 gene, which is associated with formation and progression of several tumors. Bizengri, Merus' first commercial product, is expected to be ...
The FDA has granted accelerated approval to zenocutuzumab (Bizengri, Merus N.V.) for the treatment of adults with advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC ...
Merus said the Food and Drug Administration approved Bizengri, the first treatment for adults diagnosed with pancreatic adenocarcinoma or non-small cell lung cancer that are advanced unresectable ...
On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...
Bizengri is Merus’s first approved medicine and is based on the proprietary Biclonics technology platform. Also Read: Merus Licenses US Commercialization Rights For Cancer Potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback